Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors

Last revised by Yuranga Weerakkody on 8 Mar 2021

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors which often go under the name palbociclib, ribociclib, and abemaciclib are used in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer


CDK 4 and CDK 6 are downstream agents in the estrogen signaling pathway which control entry into the cell cycle. This inhibition is thought to prevent tumor cell progression in the cell cycle.

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.